Overview

Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
0
Participant gender:
Male
Summary
OPC-1085EL ophthalmic solution, carteolol long-acting ophthalmic solution or latanoprost ophthalmic solution are administered once daily for 7 days and the effect on the blood concentration of carteolol and latanoprost in OPC-1085EL ophthalmic solution by formulating the combination drug will be determined.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Carteolol
Latanoprost
Ophthalmic Solutions
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- Subjects who are considered medically healthy per investigator's judgment

Exclusion Criteria:

- Subjects with ocular conditions as defined by the protocol

- Subjects with intraocular pressure: <10 or ≥22 mmHg